Nanollose Ltd (ASX: NC6) Share Price and News

Mr Willesee is a company director with over 20 years experience in various roles within the Australian capital markets. Mr Willesee has experience with ASX listed and other companies over a range of industries. He has expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance.

Dr Best has 40 years experience in organic chemistry both in academia, government and industry. Dr Best had took up a position with ICI Australias Research Group in Melbourne for four and a half years which included a secondment to ICI Agrochemicals in the UK. Following ICI, Wayne returned to Western Australia and spent ten years at the Chemistry Centre (WA) where he was responsible for the formation and running of the Medicinal & Biological Chemistry Section which undertook collaborative R&D into drug discovery and contract synthesis for the drug discovery and pharmaceutical industries. He then founded Epichem Pty Ltd, a contract research and drug discovery Company, which he managed for 14 years before moving full-time to Nanollose in 2018. Wayne has held appointments as an Adjunct Associate Professor at both Murdoch University and The University of Western Australia. He has served as a Director for several listed and unlisted biotechnology companies.

Mr Moullin is an executive with over two decades in legal, commercial, and corporate leadership roles. He brings a track record in strategic project execution, commercial negotiations, and corporate governance. Andrew has held senior roles at Iluka Resources Limited, DLA Piper, Macro Metals Limited, Fivemark Partners and CLSA, as well as founding and managing a range of other businesses.

-

-